Moderna (MRNA) Assets Average (2019 - 2026)

Moderna (MRNA) has 8 years of Assets Average data on file, last reported at $11.9 billion in Q1 2026.

• On a quarterly basis, Assets Average fell 11.25% year-over-year to $11.9 billion in Q1 2026; TTM through Mar 2026 was $11.9 billion, a 11.25% decrease from a year earlier, with the FY2025 full-year figure at $13.2 billion, down 18.69% from the prior year.
• Assets Average for Q1 2026 stood at $11.9 billion, down from $12.2 billion in the prior quarter.
• Over the last five years, Assets Average for MRNA reached as high as $26.8 billion in Q2 2022 and fell as low as $11.9 billion in Q1 2026.
• Historically, Assets Average has averaged $18.8 billion across 5 years, with a median of $17.6 billion in 2024.
• Across the five-year window, Assets Average surged 160.99% in 2022 and retreated 29.67% in 2024, its largest moves.
• Year by year, Assets Average stood at $26.0 billion in 2022, then declined by 27.04% to $18.9 billion in 2023, then decreased by 20.94% to $15.0 billion in 2024, then fell by 18.27% to $12.2 billion in 2025, then dropped by 2.64% to $11.9 billion in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $11.9 billion in Q1 2026, $12.2 billion in Q4 2025, and $12.1 billion in Q3 2025.